The role of the acute phase response in Docetaxel resistance in hormone-refractory prostate cancer.

急性期反应在激素难治性前列腺癌多西他赛耐药中的作用。

• 批准号: nhmrc : 1018149
• 负责人: Dr Kate Mahon
• 金额: $ 4.96万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Postgraduate Scholarships
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/role-acute-phase-prostate-cancer/109958
• 关键词: role; acute; phase; response; Docetaxel

Prostate cancer is the most common cancer in Australian men. Chemotherapy is used in advanced disease, but is only effective in ~50% of patients. In the first year of my PhD, I identified 8 plasma biomarkers that predict chemotherapy resistance. I plan to characterise how these immune molecules cause chemotherapy resistance using a mouse model of advanced prostate cancer. These markers may allow us to personalise prostate cancer treatment in the future and identify more effective therapies.

前列腺癌是澳大利亚男性最常见的癌症。化疗用于晚期疾病，但仅对约50%的患者有效。在我博士学位的第一年，我确定了8种预测化疗耐药性的血浆生物标志物。我计划使用晚期前列腺癌的小鼠模型来验证这些免疫分子是如何引起化疗耐药性的。这些标志物可能使我们能够在未来个性化前列腺癌治疗，并确定更有效的治疗方法。